Elos Medtech’s application for de-listing has been approved

Elos Medtech AB (publ)’s (“Elos Medtech” or the “Company”) application for de-listing has now been approved by Nasdaq Stockholm. The last day of trading in Elos Medtech’s shares on Nasdaq Stockholm will be 19 December 2023.

As previously announced, Elos Medtech has applied for de-listing of the Company’s shares from Nasdaq Stockholm. Nasdaq Stockholm has now approved the application and resolved that the last day of trading will be 19 December 2023.

For further information, please contact:

Stefano Alfonsi, President and CEO, +44 772 04 98 342, email: stefano.alfonsi@elosmedtech.com
Magnus René, Chairman of the Board, +1 781 266 6957, email: magnus.rene@mareadvisory.com

About Elos Medtech
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The Company operates from facilities in Sweden, Denmark, China, and the U.S. The customer base comprises international medical technology companies.

Elos Medtech has more than 650 employees and a turnover of approximately SEK 950 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989. Elos Medtech’s B share is categorized as a Health Care company on the Mid Cap list.

The information was submitted for publication, through the agency of the contact persons set out above, at 16:00 (CET) on 22 November.

Tags: